The tumor microenvironment is a dominant force in multidrug resistance

Drug Resist Updat. Feb-Apr 2012;15(1-2):39-49. doi: 10.1016/j.drup.2012.01.006. Epub 2012 Feb 13.

Abstract

The emergence of clinical drug resistance is still one of the most challenging factors in cancer treatment effectiveness. Until more recently, the assumption has been that random genetic lesions are sufficient to explain the progression of malignancy and escape from chemotherapy. Here we propose an additional perspective, one in which the tumor cells despite the malignant genome could find a microenvironment either within the tumor or as a dormant cell to remain polar and blend into an organized context. Targeting this dynamic interplay could be considered a new avenue to prevent therapeutic resistance, and may even provide a promising effective cancer treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Cell Communication / genetics*
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism*
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm / drug effects
  • Extracellular Matrix / genetics
  • Extracellular Matrix / metabolism*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Signal Transduction / genetics
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / genetics*

Substances

  • Antineoplastic Agents